first in a new class of non-pharmacologic pain treatment1

The RelieVRx Program is the first FDA-authorized VR therapy for chronic lower back pain (CLBP).2 The RelieVRx program promotes neuroplasticity and enables patients to build long-term skills to respond to pain.3

biospsychosocial icon

Rooted In Biopsychosocial Pain Education 1

The RelieVRx program is a novel adjunctive pain management program rooted in evidence-based principles for the treatment of patients living with CLBP.

safety icon

A Therapeutic Option With Fewer Trade-Offs 1,4

In clinical studies, the RelieVRx program use did not result in any serious adverse events (SAEs), with a low risk side effect profile.

at home use icon

Patient-Empowered Pain Management 1

The RelieVR program empowers patients to manage their own pain with treatment that's self-administered over 56 sessions, averaging 6 minutes each, in the comfort of their own home.

engages pain centers through Cognitive behavioral therapy (CBT) and Other proven approaches1

icon mindful

Mindful
Escapes

icon brain

Pain
Education

icon nose

Diaphragmatic
Breathing

icon meditate

Relaxation/
Interoceptive

Diaphragmatic Breathing

Responsive training environments enhance breathing techniques and allow you to connect with and control your nervous system response.1

a simple user experience at every step of the journey

Doctor icon
1. Simple to Prescribe

The prescriber simply submits the Rx form along with the required medical documentation to the AVR Pathway support team.

VR headset icon
2. Ready To Use

The RelieVRx device is delivered directly to the patient’s home, ready to use with preloaded content.

Returning shipping box icon
3. Easy To Return

Patients will return the device in the original packaging using the provided prepaid return shipping label.

Subscribe now to receive updates and educational material about the program.

Subscribe

Indication for Use  RelieVRx is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back-pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.

Contraindications

There are no known contraindications.

References

  1. Garcia LM, Birckhead BJ, Krishnamurthy P, et al. An 8-week self-administered at-home behavioral skills-based virtual reality program for chronic low back pain: double-blind, randomized, placebo-controlled trial conducted during COVID-19. J Med Internet Res. 2021;23(2):e26292. doi:10.2196/26292
  2. “Device Classification under Section 513(F)(2)(De Novo).” Accessdata.fda.gov, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=764583&lpcd=QRA.
  3. Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. Brain. 2011;134:1591-1609.
  4. Maddox, T., Oldstone, L., Sparks, C., Sackman, J., Oyao, A., Garcia, L., Maddox, R., Ffrench, K., Garcia, H., Irvin, A., Maislin, D., Keenan, B., Bonakdar, R., & Darnall, BD (2023). At-home virtual reality program for chronic lower back pain: A randomized sham-controlled effectiveness trial in a clinically severe and diverse sample. Mayo Clinic Proceedings: Digital Medicine, 2023;1(4):563-573.
  5. Maddox T, Sparks C, Oldstone L, Maddox R, Ffrench K, Garcia H, Krishnamurthy P, Okhotin D, Garcia LM, Birckhead BJ, Sackman J, Mackey I, Louis R, Salmasi V, Oyao A, Darnall BD. Durable chronic low back pain reductions up to 24 months after treatment for an accessible, 8-week, in-home behavioral skills-based virtual reality program: a randomized controlled trial. Pain Med. 2023 Oct 3;24(10):1200-1203. doi: 10.1093/pm/pnad070. PMID: 37220894; PMCID: PMC10546478.

Please see the RelieVRx program instructions for use here.